Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Mechanisms of Insulin Resistance in Humans

17 mars 2015 uppdaterad av: US Department of Veterans Affairs
The Objectives of the study are to: (1)compare the inflammatory response and insulin resistance in skeletal muscles during a systemic infusion of lipid with that during a local infusion of lipid into the femoral artery. which would cause minimal or no systemic hyperlipidemia but local plasma free fatty acid (FFA) concentrations similar to those during the systemic lipid infusion, and (2) determine the inflammatory response and insulin resistance in skeletal muscle during an infusion of lipid into the femoral artery as described above after NF-KB inhibition by high dose salicylate treatment in humans.

Studieöversikt

Status

Avslutad

Intervention / Behandling

Detaljerad beskrivning

Insulin resistance in skeletal muscle is a characteristic abnormality in obesity and the metabolic syndrome and a major factor responsible for the development of type 2 diabetes. Although the mechanisms responsible for muscle insulin resistance are largely unclear, lipid oversupply is an important factor. Among numerous potential mechanisms whereby lipid oversupply may cause muscle insulin resistance, current evidence points towards inflammation as being critical. Recent studies in animals, however, indicate that the inflammatory response in skeletal muscles may require the presence of circulating pro-inflammatory factors suggesting that the inflammation induced insulin resistance in skeletal muscles may be a secondary event. More specifically, activation of Nuclear Factor-Kappa B(NF-kB), and inflammatory master switch that drives the production of numerous pro-inflammatory cytokines in fat and liver, has been implicated in causing insulin resistance in skeletal muscles by increasing circulating pro-inflammatory cytokines. In contrast, animal studies have found that activation of NF-KB directly in skeletal muscles has no or little effect on its insulin sensitivity but does produce other abnormalities such as increased proteasome activity. The study shall therefore be undertaken to determine to what extent lipid-induced inflammation and insulin resistance in skeletal muscles requires the presence of circulating proinflammatory factors in humans.

Studietyp

Observationell

Inskrivning (Faktisk)

25

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Arizona
      • Phoenix, Arizona, Förenta staterna, 85012
        • Phoenix VA Health Care System Carl T. Hayden VA Medical Center, Phoenix, AZ

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

21 år till 65 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

healthy subjects

Beskrivning

Inclusion Criteria:

  • two groups of 16 healthy subjects

Exclusion Criteria:

  • diabetes or impaired glucose tolerance
  • peripheral vascular disease
  • pulmonary disease
  • clinically significant hepatic or renal disease
  • triglycerides >200mg/dl
  • anemia
  • abnormal PT, PTT or INR
  • pregnancy or lactation

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Group 1
healthy subjects
lipid infusion
Group 2
healthy subjects different from group 1
lipid infusion

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Insulin Signaling With Lipid Infusion
Tidsram: 4 h
IRS-1 expression in response to femoral lipid infusion in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blot bands, normalized to a housekeeping protein, GAPDH, in control and treated groups.
4 h
Phos-p38 MAPK Expression With Femoral Lipid and Insulin Infusions
Tidsram: 4 h
Phosphorylation of p38 MAPK in response to femoral lipid and insulin infusions. phospho-p38 MAPK expression in response to femoral lipid infusion in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.
4 h
p38 MAPK Expression With Femoral Lipid and Insulin Infusions
Tidsram: 4 h
p38 MAPK expression in response to femoral lipid and insulin infusions in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.
4 h
Phospho-ERK MAPK Expression With Femoral Lipid and Insulin Infusions
Tidsram: 4 h
Phosphorylation of ERK MAPK in response to femoral lipid and insulin infusions in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.
4 h
ERK MAPK Expression With Femoral Lipid and Insulin Infusions
Tidsram: 4 h
ERK MAPK expression in response to femoral lipid and insulin infusions in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.
4 h
Phospho-JNK MAPK Expression With Femoral Lipid and Insulin Infusions
Tidsram: 4 h
Phosphorylation of JNK MAPK in response to femoral lipid and insulin infusions in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.
4 h
JNK MAPK Expression With Femoral Lipid and Insulin Infusions
Tidsram: 4 h
JNK MAPK expression in response to femoral lipid and insulin infusions in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.
4 h

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Charles C Oh, MD, Phoenix VA Health Care System Carl T. Hayden VA Medical Center, Phoenix, AZ

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 april 2006

Primärt slutförande (Faktisk)

1 januari 2012

Avslutad studie (Faktisk)

1 augusti 2014

Studieregistreringsdatum

Först inskickad

26 maj 2006

Först inskickad som uppfyllde QC-kriterierna

26 maj 2006

Första postat (Uppskatta)

29 maj 2006

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

3 april 2015

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

17 mars 2015

Senast verifierad

1 mars 2015

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Inflammation

Kliniska prövningar på 20% Intralipid

3
Prenumerera